Overview of Agents with Efficacy in Binge Eating

Obesity and Mental Disorders

Volumn , Issue , 2006, Pages 289-306

  Appolinario, Jose C ^a   Bacaltchuk, Josue ^b  

^a Institute of Psychiatry   (Brazil)

^b University of Sã O Paolo   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85039120847     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849374517-17     Document Type: Chapter

References (86)

1. Stunkard AJ. Eating patterns and obesity. Psychiatr Q 1959; 33:284-295.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Associa-tion, 1994.ss
3. de Zwaan M. Binge eating disorder and obesity. Int J Obes Relat Metab Disord 2001; 25(Suppl l):S51-55.
4. de Zwaan M, Mitchell JE, Seim HC, et al. Eating related and generai psycho-pathology in obese females with binge-eating disorder. Int J Eat Disord 1994; 15(l):43-52.
5. Eldredge KL, Agras WS. Weight and shape overconcern and emotional eating in binge-eating disorder. Int J Eat Disord 1996; 19(l):73-82.
6. Yanovski SZ, Nelson JE, Dubbert BK, et al. Association of binge-eating disorder and psychiatric comorbidity in obese subjects. Am J Psychiatry 1993; 150:1472-1479.
7. Fontenelle LF, Mendlowicz MV, de Menezes GB, et al. Psychiatric comorbidity in a Brazilian sample of patients with binge-eating disorder. Psychiatry Res 2003; 15:119(12):189-194.
8. Bulik CM, Sullivan PF, Kendler KS. Medical and psychiatric morbidity in obese women with and without binge-eating. Int J Eat Disord 2002; 32(l):72-78.
9. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50:143-151.
10. McElroy SL, Keck PE, Phillips KA. Kleptomania, compulsive buying, and binge-eating disorder. J Clin Psychiatry 1994; 56(Suppl 4):S14-S26.
11. Steiger H, Lehoux PM, Gauvin L. Impulsivity, dietary control and the urge to binge in bulimic syndromes. Int J Eat Disord 1999; 26(3):261-274.
12. Sansone RA, Wiederman MW, Sansone LA. The prevalence of borderline per-sonality disorder among individuals with obesity: a critical review of the litera-ture. Eat Behav 2000; l(l):93-104.
13. Sansone RA, Wiederman MW, Monteith D. Obesity, borderline personality symptomatology, and body image among women in a psychiatric outpatient setting. Int J Eat Disord 200; 29(l):76-79.
14. Devlin MJ. binge-eating disorder and obesity. A combined treatment approach. Psychiatr Clin North Am 2001; 24:325-335.
15. Zhu AJ, Walsh BT. Pharmacologic treatment of eating disorders. Can J Psy-chiatry 2002; 47(3):227-234.
16. Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge-eating disorder. Curr Drug Targets 2004; 5(3):301-307.
17. McCann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am J Psychiatry 1990; 147(ll):1509-1513.
18. Alger SA, Schwalberg MD, Bigaoueette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normal weight bulimic and obese, binge-eating subjects. Am J Clin Nutr 1991; 53:865-867.
19. Hudson JI, McElroy SL, Raymond, NC. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled double-blind trial. Am J Psychiatry 1998; 155:1756-1762.
20. McElroy SL, Casuto LS, et al. Placebo-controled trial of sertraline in the treatment of binge-eating disorder. Am J Psychiatry 2000; 157:1004-1006.
21. Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002; 63:1028-1033.
22. McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr. Cita-lopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry 2003; 64(7):807-813.
23. Pearlstein T, Spurell E, Hohlstein LA, et al. A double-blind, placebo-controlled trial of fluvoxamine in binge-eating disorder: a high placebo response. Arch Women Ment Health 2003; 6(2):147-151.
24. Stunkard A, Berkowitz R, Tanrikut C, Reiss E, Young L. d-Fenfluramine treatment of binge-eating disorder. Am J Psychiatry 1996; 153:1455-1459.
25. Appolinario JC, Godoy-Matos A, Fontenelle LF, et al. An open-label trial of sibutramine in obese patients with binge-eating disorder. J Clin Psychiatry 2002; 63(l):28-30.
26. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60(11):1109-1116.
27. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61(5):368-372.
28. Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry 2001; 158(6):967-968.
29. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge-eating disorder: an open study. Can J Psychiatry 2002; 47:271-273.
30. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge-eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2):255-261.
31. McElroy SL, Sapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. Presented at 2004 International Conference on Eating Disorders, Orlando, Florida: April 30, 2004.
32. McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Jr. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004; 65(1):50-56.
33. Raingeard I, Courtet P, Renard E, Bringer J. Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders. Diabetes Care 2004; 27(3):847-848.
34. Versiani M. A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). World J Biol Psychiatry 2000; l(l):27-33.
35. Jacobs MJ, Wilfley DE, Gregory-Bills T, et al. Placebo response in pharma-cotherapy for binge-eating disorder. Presented at 2003 International Confer-ence on Eating Disorders, Denver, Colorado: May 29-31, 2003.
36. Williamson DA, Womble LG, Smeets MA, et al. Latent structure of eating disorder symptoms: a factor analytic and taxometric investigation. Am J Psychiatry 2002; 159(3):412-418.
37. Appolinario JC, Bueno JR, Coutinho W. Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs 2004; 18(10):629-651.
38. Gardiner HM, Freeman CP, Jesinger DK, Collins SA. Fluvoxamine: an open pilot study in moderately obese female patients suffering from a typical eating disorders and episodes of bingeing. Int J Obes Relat Metab Disord 1993; 17(5):301-305.
39. Carter WP, Hudson JI, Lalonde JK, Pindyck L, McElroy SL, Pope HG Jr. Pharmacologic treatment of binge-eating disorder. Int J Eat Disord 2003; 34 (Suppl):S74-88.
40. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002; 52(12):1166-1174.
41. Malhotra S, King KH, Welge JA, Brusman-Lovins L, McElroy SL. Venlafax-ine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry 2002; 63(9):802-826.
42. Silveira RO. Reboxetine in obese patients with binge-eating disorder. MSc dissertation, Federal University of Rio Grande do Sul, Porto Alegre, 2004.
43. Quinn JG, O'Hare E, Levine AS, Kim EM. Evidence for a mu-opioid-opioid connection between the paraventricular nucleus and ventral tegmental area in the rat. Brain Res 2003; 991(1-2):206-211.
44. Jarosz PA, Metzger BL. The effect of opioid antagonism on food intake beha-vior and body weight in a biobehavioral model of obese binge-eating. Biol Res Nurs 2002; 3(4):198-209.
45. de Zwaan M, Mitchell JE. Opiate antagonists and eating behavior in humans: a review. J Clin Pharmacol 1992; 32(12):1060-1072.
46. Marrazzi MA, Markham KM, Kinzie J, Luby ED. binge-eating disorder: response to naltrexone. Int J Obes Relat Metab Disord 1995; 19(2):143-145.
47. Neumeister A, Winkler A, Wober-Bingol C. Addition of naltrexone to fluoxetine in the treatment of binge-eating disorder. Am J Psychiatry 1999; 156(5):797.
48. Guss JL, Kissileff HR, Devlin MJ, Zimmerli E, Walsh BT. Binge size increases with body mass index in women with binge-eating disorder. Obes Res 2002; l0(10):1021-1029.
49. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002; 95(l):73-88.
50. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4(3):263-270.
51. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356(9248):2119-2125.
52. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3(Suppl 4):553S-559S.
53. Mitchell JE, Gosnell BA, Roerig JL, et al. Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. Obes Res 2003; 11(5):599-602.
54. Ghaemi SN, Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers? Harv Rev Psychiatry 2000; 8(l):l-7.
55. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62(3):199-203.
56. Bergen DC, Ristanovic RK, Waicosky K, Kanner A, Hoeppner TJ. Weight loss in patients taking felbamate. Clin Neuropharmacol 1995; 18(l):23-27.
57. French JA. The role of new antiepileptic drugs. Am J Manag Care 2001; 7(Suppl 7):S209-S214.
58. Pellock JM, Appleton R. Use of new antiepileptic drugs in the treatment of childhood epilepsy. Epilepsia 1999; 40(Suppl 6):S29-S38.
59. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; ll(6):722-733.
60. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289(14):1820-1825.
61. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64(11):1335-1341.
62. Green RS, Rau JH. Treatment of compulsive eating disturbances with anticon-vulsant medication. Am J Psychiatry 1974; 131(4):428-432.
63. Wermuth BM, Davis KL, Hollister LE, Stunkard AJ. Phenytoin treatment of the binge-eating syndrome. Am J Psychiatry 1977; 134(11):1249-1253.
64. Kaplan AS, Garfinkel PE, Darby PL, Garner DM. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983; 140(9):1225-1226.
65. Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997; 31(10):1164-1173.
66. Oommen KJ, Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuro-pharmacol 1999; 22:192-200.
67. Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000; 355(9206):792-797.
68. Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000; 61(Suppl 11):9-17.
69. Zarrindast MR, Hosseini-Nia T. Anorectic and behavioural effects of bupro-pion. Gen Pharmacol 1988; 19(2):201-204.
70. Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan. Bupropion for weight loss: an investigation of efficacy and tolerabil-ity in overweight and obese women. Obes Res 2001; 9(9):544-551.
71. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10(7):633-641.
72. Horne RL, Ferguson JM, Pope HG, et al. Treatment of bulimia with bupro-pion: a multicenter controlled trial. J Clin Psychiatry 1988; 49(7):262-266.
73. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995; 152(5):792-794.
74. Gelber D, Levine J, Belmaker RH. Effect of inositol on bulimia nervosa and binge-eating. Int J Eat Disord 2001; 29(3):345-348.
75. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64(12):1426-1435.
76. Shisslak CM, Perse T, Crago M. Coexistence of bulimia nervosa and mania: a literature review and case report. Compr Psychiatry 1991; 32(2):181-184.
77. Hsu LK, Clement L, Santhouse R, Ju ES. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis 1991; 179(6):351-355.
78. Bacaltchuk J, Trefiglio RP, Oliveira IR, Hay P, Lima MS, Mari JJ. Combina-tion of antidepressants and psychological treatments for bulimia nervosa: a systematic review. Acta Psychiatr Scand 2000; 101(4):256-264.
79. de Zwaan M, Roerig J. Pharmacological treatment of eating disorders: a review. In: Maj M, Halmi K, Lopez-Ibor JJ, Sartorius N, eds. Eating Disorders: WPA Series—Evidence and Experience in Psychiatry. London: John Wiley & Sons Ltd, 2003.
80. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry 1990; 147(7):876-881.
81. Agras WS, Telch CF, Arnow B, et al. Weight loss, cognitive-behavioral, and desipramine treatments in binge-eating-disorder. An additive design. Behav Ther 1994; 25:225-238.
82. Devlin MJ, Goldfein JA, Carino JS, Wolk SL. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord 2000; 28(3):325-332.
83. Laederach-Hofmann K, Graf C, Horber F, et al. Imipramine and diet counsel-ing with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord 1999; 26(3):231-244.
84. Ricca V, Mannucci E, Mezzani B, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge-eating disorder: a one-year follow-up study. Psychother Psychosom 2001; 70(6):298-306.
85. Schmidt do Prado-Lima PA, Bacaltchuk J. Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord 200; 4(4):271-273.
86. Anghelescu I, Klawe C, Szegedi A. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. J Clin Psychopharmacol 2002; 22(5):52.